Skip to content

Study · Non-randomized trial · 2007

9 results

[Clinical and pharmacoeconomic peculiarities of the treatment with cerebrolysin in the period of rehabilitation of is ischemic stroke.].

Gusev EI, Gekht AB, Belousov IuB, Pavlov NA, Galanov DV, Popov GR, Mil'chakova LE

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2007

PMID18477976 (opens in a new tab)PepBankPUB-18477976
Publisher pageAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients undergoing ischemic stroke rehabilitation, cerebrolysin at 10 ml daily significantly reduced neurological disturbances compared with controls.

    In plain wordsIn patients after ischemic stroke, cerebrolysin at 10 ml daily reduced neurological problems more than control treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological disturbances at 10 ml daily
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml dailyAs given in this study (human).

    Source sentences

    Summary
    The results of the clinical and pharmacoeconomic study of cerebrolysin in the rehabilitative therapy of ischemic stroke presented in the paper revealed the statistically significant regress of neurological disturbances in patients receiving cerebrolysin in daily dosages of 10 and 20 ml as compared to the control group.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients undergoing ischemic stroke rehabilitation, cerebrolysin at 20 ml daily significantly reduced neurological disturbances compared with controls.

    In plain wordsIn patients after ischemic stroke, cerebrolysin at 20 ml daily reduced neurological problems more than control treatment.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNeurological disturbances at 20 ml daily
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    20 ml dailyAs given in this study (human).

    Source sentences

    Summary
    The results of the clinical and pharmacoeconomic study of cerebrolysin in the rehabilitative therapy of ischemic stroke presented in the paper revealed the statistically significant regress of neurological disturbances in patients receiving cerebrolysin in daily dosages of 10 and 20 ml as compared to the control group.
  3. 03HumanNon-randomized trialEfficacy outcome

    In stroke rehabilitation patients, cerebrolysin accelerated motor recovery more than sensory recovery compared with basic antihypertensive and antiaggregate therapy.

    In plain wordsIn stroke patients, cerebrolysin accelerated motor recovery more than sensory recovery compared with basic antihypertensive and antiaggregate therapy.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseMotor versus sensory rehabilitation
    Study

    n: not reported in source

    Comparator
    Basic antihypertensive and antiaggregate therapy
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The rehabilitation of motor functions was more rapid than sensitive ones in patients receiving cerebrolysin comparing to those switched to the basic antihypertensive and antiaggregate therapy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In stroke rehabilitation patients, cerebrolysin treatment was associated with positive speech rehabilitation dynamics.

    In plain wordsIn stroke patients, cerebrolysin treatment was linked to improved speech rehabilitation.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseSpeech rehabilitation
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The positive dynamics of speech rehabilitation was observed, the regress of aphatic disturbances being more significant for daily dosage of 20 ml.
  5. 05HumanNon-randomized trialEfficacy outcome

    In stroke rehabilitation patients, regression of aphatic disturbances was more significant with cerebrolysin at 20 ml daily.

    In plain wordsIn stroke patients, speech disturbances decreased more significantly with cerebrolysin at 20 ml daily.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAphatic disturbance regression at 20 ml daily
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    20 ml dailyAs given in this study (human).

    Source sentences

    Summary
    The positive dynamics of speech rehabilitation was observed, the regress of aphatic disturbances being more significant for daily dosage of 20 ml.
  6. 06HumanNon-randomized trialEfficacy outcome

    In stroke rehabilitation patients, rehabilitation rate was higher with cerebrolysin at 20 ml daily than at 10 ml daily.

    In plain wordsIn stroke patients, recovery was faster with cerebrolysin at 20 ml daily than at 10 ml daily.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRehabilitation rate at 20 versus 10 ml
    Study

    n: not reported in source

    Comparator
    Cerebrolysin 10 ml daily
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    20 ml dailyAs given in this study (human).

    Source sentences

    Summary
    Rehabilitation rate in the period of treatment with cerebrolysin was higher for daily dosage of 20 ml than that of 10 ml.
  7. 07HumanNon-randomized trialEfficacy outcome

    In stroke rehabilitation patients, cerebrolysin produced prolonged effects after withdrawal and higher rehabilitation rates through the 11th week than controls.

    In plain wordsIn stroke patients, cerebrolysin effects persisted after treatment, with higher recovery rates through the 11th week than controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRehabilitation rate through week 11
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A prolonged effect of the drug during the long period after its withdrawal was found that resulted in higher rates of rehabilitation to the 11th week in patients receiving cerebrolysin as compared to the control group.
  8. 08HumanNon-randomized trialOther

    In stroke rehabilitation patients, direct medical expenses were higher in cerebrolysin groups than controls, particularly with the 20 ml dosage.

    In plain wordsIn stroke patients, direct medical costs were higher with cerebrolysin than control treatment, especially with the 20 ml dosage.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDirect medical expenses
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Average total cost of direct medical expenses per a patient estimated in the pharmacoeconomic analysis for the groups receiving cerebrolysin and the control group was higher in the former groups, in particular in that with 20 ml dosage of cerebrolysin.
  9. 09HumanNon-randomized trialOther

    In stroke rehabilitation patients, the cost of cerebrolysin treatment per effective unit on the Lindmark and Barthel scales was less than or comparable with controls.

    In plain wordsIn stroke patients, the cost of cerebrolysin treatment per scale point on the Lindmark and Barthel scales was lower than or similar to control treatment.

    Peptide
    Cerebrolysin
    Outcome
    MixedCost per effective unit (Lindmark and Barthel scale scores)
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A cost-efficacy analysis revealed that the cost of cerebrolysin treatment per effective unit (a cost of one score on the Lindmark scale and the Barthel scale) was less or comparable in patients receiving cerebrolysin comparing to the control group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.